{"id":"oltipraz-2-120mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oltipraz acts as a potent inducer of NAD(P)H quinone oxidoreductase (NQO1) and glutathione S-transferases (GSTs), which are phase II detoxification enzymes. By upregulating these cytoprotective pathways, it enhances cellular defense against oxidative stress, electrophilic compounds, and carcinogenic agents. This mechanism has been explored primarily for chemoprevention in high-risk populations.","oneSentence":"Oltipraz is an organosulfur compound that induces phase II detoxification enzymes and antioxidant pathways to protect cells from oxidative stress and carcinogenic damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:10.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma chemoprevention in patients with chronic hepatitis B"},{"name":"Aflatoxin-related cancer prevention"}]},"trialDetails":[{"nctId":"NCT02068339","phase":"PHASE3","title":"Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis","status":"COMPLETED","sponsor":"PharmaKing","startDate":"2014-02","conditions":"Non-alcholic Fatty Liver Disease","enrollment":283}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oltipraz 2 (120mg)","genericName":"Oltipraz 2 (120mg)","companyName":"PharmaKing","companyId":"pharmaking","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oltipraz 2 (120mg) is being studied in a clinical trial for its efficacy and safety in reducing liver fat in patients with non-alcoholic fatty liver disease. The study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}